meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) 3

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone

versus all
vs immune chekpoint inhibitors
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -